Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 10/20 | 0.77 |
| ▸ | AGTR1 | P30556 | 9/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787257 | 0.93 | AGTR2 (0.78) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL10281258 | 0.91 | AGTR2 (0.76) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL94332 | 0.90 | AGTR1 (0.74) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL1640019 | 0.88 | AGTR2 (0.79) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL17031397 | 0.88 | AGTR2 (0.77) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28341316 | 0.87 | AGTR1 (1.00) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL8244120 | 0.87 | AGTR2 (0.76) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL29087653 | 0.87 | AGTR1 (1.00) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL16403 | 0.87 | AGTR1 (1.00) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28754180 | 0.86 | AGTR1 (0.99) | AGTR2AGTR1ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905770-A1 | A process for the preparation of phenyltetrazole compounds | Dipharma Francis S.r.l. (IT) | 2008-04-02 | — | — | EP | disclosed |
| US-20080076932-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE COMPOUNDS | DIPHARMA FRANCIS S.R.L. (IT) | 2008-03-27 | — | — | US | disclosed |
| US-20080076932-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE COMPOUNDS | DIPHARMA FRANCIS S.R.L. (IT) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076932-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE COMPOUNDS | CYP4A11, PPOX, CYP11B2 | AGTR2 51/4885AGTR1 74/4885ABCC3 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.